Weighing Treatment Decisions Based on Neurofilament Light Chain Levels

Opinion
Video

This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.

Thought leaders explore treatment possibilities in patients with irregular NFL patterns.

In this segment, experts discuss a scenario where a patient on a platform drug experiences a significant rise in NFL levels along with the identification of two new lesions on MRI. Ahmed Obeidat, MD, PhD, responds by stating that such a situation would trigger a conversation with the patient about potentially escalating therapy. He emphasizes the importance of considering biomarkers of neuroaxonal damage and the need for personalized treatment decisions.

They note the lack of standardized guidance on what constitutes a significant change on an MRI. He also highlights potential confounders like age, smoking, diabetes, renal disease, and pregnancy that may influence NFL levels. Tanuja Chitnis, MD, adds that other neurological diseases and comorbidities should be considered as well.

The discussion underscores the complexity of interpreting changes in NFL levels and the need to factor in various patient-specific variables and confounders. The dialogue maintains a clinical and informative tone, aligning with the user's preference for accuracy and professionalism.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.

This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Related Videos
Monica Verduzco-Gutierrez, MD
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
Michael Levy, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.